Thermo Fisher Scientific is investing $50 million in its St. Louis, MO, site, one of the company’s Centers of Excellence (COE) for Biological Commercial Manufacturing. The investment is part of a strategy to continue expansion of the company’s global network of biologic drug substance capabilities for clinical and commercial supply.
The project includes expansion to the existing manufacturing building #2 by 64,000 square feet, which will double its manufacturing capacity and will be operational in 2019. The expansion will take advantage of the Thermo Fisher bioproduction “eco-system” for bioreactors, consumables, and factory automation.
With the capacity expansion, Thermo Fisher will have the second largest base of single-use bioproduction capacity at a CDMO in the world. The investment also will allow for further expansion in the future. Approximately 80 new technical jobs are expected to be added.
“Biologics have the potential to benefit millions of patients around the world,” said Michel Lagarde, president of pharma services for Thermo Fisher. “Patheon Biologics, with this expansion, will be better equipped to meet the needs of our customers and ultimately the patients who rely on these life-saving therapies.”
The Patheon Biologics Network of four sites around the globe is growing and has standardized on the 2000L, single-use platform as the preferred option in new drug development through to commercialization. The St Louis site currently provides process development, clinical cGMP manufacturing, and commercial manufacturing using both fed batch and perfusion processes. The St. Louis COE has in-house analytical capabilities for Quality Assurance and Quality Control.
“Thermo Fisher’s investment in the Patheon Biologics Network is a recognition of the extremely strong growth in demand for outsourced biologic development and commercial manufacturing,” said Stephen Lam, head of biologics, who added that over the last two years, the company has doubled manufacturing capacity at all of its locations, including the St. Louis site.
Thermo Fisher’s Pharma Services develops solutions and business models to help customers manage the clinical development process and provides flexible manufacturing options to address client needs in an evolving marketplace. The biologics network is complemented by a global network of sites to formulate and manufacture sterile injectable drug product for clinical trials and commercial supply.
(Source: Thermo Fisher Scientific)